1. Home
  2. CGON vs NIC Comparison

CGON vs NIC Comparison

Compare CGON & NIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • NIC
  • Stock Information
  • Founded
  • CGON 2010
  • NIC 2000
  • Country
  • CGON United States
  • NIC United States
  • Employees
  • CGON N/A
  • NIC N/A
  • Industry
  • CGON
  • NIC Major Banks
  • Sector
  • CGON
  • NIC Finance
  • Exchange
  • CGON NYSE
  • NIC Nasdaq
  • Market Cap
  • CGON 2.1B
  • NIC 1.8B
  • IPO Year
  • CGON 2024
  • NIC N/A
  • Fundamental
  • Price
  • CGON $25.55
  • NIC $116.70
  • Analyst Decision
  • CGON Strong Buy
  • NIC Buy
  • Analyst Count
  • CGON 10
  • NIC 4
  • Target Price
  • CGON $64.44
  • NIC $119.25
  • AVG Volume (30 Days)
  • CGON 784.3K
  • NIC 59.9K
  • Earning Date
  • CGON 08-07-2025
  • NIC 07-15-2025
  • Dividend Yield
  • CGON N/A
  • NIC 1.09%
  • EPS Growth
  • CGON N/A
  • NIC 28.66
  • EPS
  • CGON N/A
  • NIC 8.31
  • Revenue
  • CGON $662,000.00
  • NIC $352,932,000.00
  • Revenue This Year
  • CGON N/A
  • NIC N/A
  • Revenue Next Year
  • CGON $14,719.70
  • NIC $4.08
  • P/E Ratio
  • CGON N/A
  • NIC $14.16
  • Revenue Growth
  • CGON 224.51
  • NIC 9.54
  • 52 Week Low
  • CGON $14.80
  • NIC $77.49
  • 52 Week High
  • CGON $40.47
  • NIC $125.50
  • Technical
  • Relative Strength Index (RSI)
  • CGON 48.31
  • NIC 42.54
  • Support Level
  • CGON $25.02
  • NIC $115.57
  • Resistance Level
  • CGON $26.97
  • NIC $118.58
  • Average True Range (ATR)
  • CGON 1.14
  • NIC 2.11
  • MACD
  • CGON -0.18
  • NIC -0.55
  • Stochastic Oscillator
  • CGON 17.79
  • NIC 16.97

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

Share on Social Networks: